Clinical trialNCT03673124Active, not recruitingPhase 2Interventional

Ribociclib and Letrozole Treatment in Ovarian Cancer

SponsorGynecologic Oncology GroupEnrollment51Low Grade Serous Carcinoma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The study evaluates the response to treatment with Ribociclib and Letrozole in patients with low grade serous cancer of the ovary, fallopian tube or peritoneum.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Brian Slomovitz, MD
GOG
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

27 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of California, San Francisco
San Francisco, California, United States
Uf Heath
Gainesville, Florida, United States
Moffitt Cancer Center
Tampa, Florida, United States
Northside Hospital
Atlanta, Georgia, United States
Northshore University Healthsystem
Evanston, Illinois, United States
Saint Vincent Hospital and Health Care Center, Inc.
Indianapolis, Indiana, United States
St. Joseph Mercy Hospital Cancer Care Center
Ann Arbor, Michigan, United States
Mayo Clinic - Rochester
Rochester, Minnesota, United States
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, United States
Hackensack University Medical Center
Hackensack, New Jersey, United States
the Valley Hospital Inc.
Ridgewood, New Jersey, United States
New Mexico Cancer Care Alliance/university of New Mexico Comprehensive Cancer Center
Albuquerque, New Mexico, United States
Southwest Gynecologic Oncology Associates
Albuquerque, New Mexico, United States
Miami Valley Hospital
Centerville, Ohio, United States
the Ohio State Comprehensive Cancer Center
Columbus, Ohio, United States
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States
Oklahoma Cancer Care Specialists and Research Institute , Llc
Tulsa, Oklahoma, United States
Western Pennsylvania Hospital/west Penn Hospital
Pittsburgh, Pennsylvania, United States
Abington Memorial Hospital
Willow Grove, Pennsylvania, United States
Women & Infants Hospital
Providence, Rhode Island, United States
Parkland Health and Hospital System
Dallas, Texas, United States
University of Texas Southwestern Medical Center
Dallas, Texas, United States
Houston Methodist Hospital
Houston, Texas, United States
Houston Methodist Willowbrook Hospital
Houston, Texas, United States
Md Anderson Cancer Center
Houston, Texas, United States
Memorial Hermann Texas Medical Center - Texas Medical Center
Houston, Texas, United States
Houston Methodist Sugar Land Hospital
Sugar Land, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Letrozole →Ribociclib →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 20 May 2019
Primary completion: 23 Dec 2024
Completion: 31 Dec 2026
Last update posted: 23 Dec 2025
Registered enrollment: 51
Registry id: NCT03673124

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.